Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
myelodysplastic syndrome (MDS)
Biotech
Geron secures 12-2 AdComm vote in favor of blood cancer drug
The biotech won over an FDA advisory committee and secured a 12 to 2 vote in its favor—triggering a surge in its share price.
Nick Paul Taylor
Mar 15, 2024 5:00am
FDA questions benefit-risk profile of Geron's imetelstat
Mar 12, 2024 12:20pm
Roivant's Hemavant bet winds down after cutting ex-Eisai drug
Feb 13, 2024 2:01pm
BMS snags another ADC with modest $100M Orum deal
Nov 6, 2023 7:00am
After 2 partners walk away, Syros cuts 35% of workforce
Oct 2, 2023 11:06am
Gilead's magrolimab once again placed on partial clinical hold
Aug 21, 2023 9:50am